08:46 AM EDT, 07/22/2025 (MT Newswires) -- Charles River Laboratories International ( CRL ) said Tuesday it has signed a plasmid DNA manufacturing agreement with Elly's Team to support a phase 1 clinical trial for neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures, or NEDAMSS, a rare genetic disorder.

The partnership, which is part of Charles River's CGT Accelerator program, will provide gene therapy contract development and manufacturing organization services and advisory support to manufacture materials needed for trial.

Charles River also said Elly's Team will use its ready-made DNA tools to speed up production and make the process more efficient.

Shares of Charles River were up over 5% in recent Tuesday premarket activity.

Price: 158.00, Change: +8.27, Percent Change: +5.53